Efficacy of peroxisome proliferator-activated receptor agonists, glucagon-like peptide-1 receptor agonists, or sodium-glucose cotransporter-2 inhibitors for treatment of non-alcoholic fatty liver disease: A systematic review
Is allulose gut-friendly
Yes, certain agents like semaglutide are FDA-approved for chronic weight management in people without diabetes
GLP-1 is contraindicated in patients including but not limited to: those with a personal or family history of medullary thyroid cancer, patients with multiple endocrine neoplasia type 2, patients with a hypersensitivity reaction to GLP-1 or any of the product components, as well as patients with pancreatitis, kidney disease, diabetic retinopathy or gallbladder disease
In midlife, it often shows up as perimenopausal symptoms or a gradual decline in testosterone
But for most people, continuing GLP-1s is necessary to maintain your new lower weight